Carl brings experience in late-stage drug development in orphan diseases having served in senior roles in both large international pharma companies such as Sanofi, Genzyme and Lundbeck as well as in the Swedish biotech company Wilson Therapeutics as CMO. Carl is a Medical Doctor (M.D.) and holds a PhD degree from University of Linköping.

“I look forward to joining Ascelia Pharma and to contribute in its mission to improve the lives of patients living with cancer. Ascelia has two promising drug candidates, one in late-stage clinical development  and one in earlier stage and I’m strongly motivated to advance the development of these and bring them to patients”, says Carl Bjartmar.